GLP1R and type 2 diabetes mellitus: In a mouse model of ischemic stroke, Semaglutide (an FDA approved GLP-1R agonist for type-2 diabetes mellitus) administration (30 nM/kg every 5 days until 28 days) significantly reduced levels of inflammatory cytokines (IL-1α, TNFα, and C1q), Iba-1+ microglia/macrophages, and C3d+/GFAP+ A1 reactive astrocytes (Zhang et al., 2022).